This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participa…

Catecholaminergic Polymorphic Ventricular Tachycardia

~Estimated

~$10 – $8,750

Solid Biosciences Inc.NCT07148089

Phase 2

A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability,…

Catecholaminergic Polymorphic Ventricular Tachycardia

~Estimated

~$10 – $8,750

Cardurion Pharmaceuticals, Inc.NCT06658899